Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 597-602

  Bommakanti, Satya V ^a   Dudek, Arkadiusz Z ^a,d   Khatri, Amit ^b   Kirstein, Mark N ^b,c   Gada, Purvi D ^a  

^a Oncology and Transplantation   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

bortezomib; cancer; clinical trial; elderly; gemcitabine

Indexed keywords

BICALUTAMIDE; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ESTRAMUSTINE; GEMCITABINE; HALICHONDRIN B; IFOSFAMIDE; IXABEPILONE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE;

ADENOID CYSTIC CARCINOMA; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLADDER CANCER; BONE PAIN; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; CYTOPENIA; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EDEMA; EPIGASTRIC PAIN; FATIGUE; FEMALE; HEAD AND NECK ADENOCYSTIC CARCINOMA; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HYPOXIA; KIDNEY FAILURE; LOWER EXTREMITY EDEMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORCHIECTOMY; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; SOLID TUMOR; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; UTERUS SARCOMA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PYRAZINES;

EID: 81855185341     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181f9441f     Document Type: Article

References (32)

1. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer. 2007;43:1125-1133.
2. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS- 341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9: 1136-1144.
3. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
4. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11: 164-179.
5. Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005;5:4902-4908.
6. Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003;22: 4953-4963.
7. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004;109: 182-188.
8. Kurdow R, Schniewind B, Zoefelt S, et al. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression. Langenbecks Arch Surg. 2005;390: 243-248.
9. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev. 2003;29:41-48.
10. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block thegrowth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004;3:279-290.
11. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS- 341 in cancer therapy. Clin Cancer Res. 1999;5:2638-2645.
12. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535-3540.
13. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000.
14. Nawrocki ST, Sweeney-Gotsch B, Takamori R, et al. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004;3:59-70.
15. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50:183-193.
16. Davies AM, Chansky K, Lara PN Jr, et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced nonsmall cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009;4:87-92.
17. Voortman J, Smit EF, Honeywell R, et al. A parallel doseescalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res. 2007;13:3642-3651.
18. Davies AM, Ruel C, Lara PN, et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008;3:68-74.
19. Ryan DP, Appleman LJ, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006;107:2482-2489.
20. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol. 2007;25:1898-1907.
21. Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancerpatients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother. 2009;7:151-158.
22. Balducci L. Pharmacology of antineoplastic medications in older cancer patients. Oncology. 2009;23:78-85.
23. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997;80:1317-1322.
24. Messersmith WA, Baker SD, Lassiter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006;12:1270-1275.
25. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108-2121.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
27. Kirstein MN, Hassan I, Guire DE, et al. High-performance liquid chromatographic method for the determination of gemcitabine and 20,20-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835: 136-142.
28. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software, in Biomedical Simulations Resource, Los Angeles. 1997.
29. Luu T, Chow W, Lim D, et al. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Res. 2010;30:167-174.
30. Veltkamp SA, Pluim D, van Eijndhoven MA, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 20,20-difluorodeoxyuridine. Mol Cancer Ther. 2008;7: 2415-2425.
31. Pauwels B, Korst AE, Lambrechts HA, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol. 2006;58:219-228.
32. Venook AP, Egorin MJ, Rosner GL, et al., Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780-2787. Abstract.